Artal Group’s Passage Bio PASG Stock Holding History

Artal Group’s Portfolio PASG Stock Details PASG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-782	Closed	-$205K	–	147
2020 Q3	$205K	Sell	782 -10,918	-93%	-$3.76M	0.01%	133
2020 Q2	$6.39M	Sell	11,700 -800	-6%	-$360K	0.18%	94
2020 Q1	$3.94M	Buy	+12,500	New	+$3.91M	0.17%	83

Other funds holding PASG

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HCM

Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Artal Group's PASG Position: Q4 2020 in Review

Artal Group sold out of Passage Bio (PASG) in Q4 2020, closing a stake of 782 shares — an estimated $205K sold.

Artal Group first reported a position in PASG in Q1 2020 and held it in 3 quarters. The position peaked at $6.39M in Q2 2020. 71 funds tracked by Wall St. Rank hold PASG as of Q4 2020.

Artal Group reported no remaining Passage Bio position as of Q4 2020 after selling out during the quarter.
Artal Group sold 782 Passage Bio shares in Q4 2020, an estimated $205K.
Artal Group first reported a position in Passage Bio in Q1 2020 and held it in 3 quarters.
Artal Group's Passage Bio position peaked at $6.39M in Q2 2020.
71 funds tracked by Wall St. Rank held Passage Bio as of Q4 2020.

Based on Artal Group's 13F filing for Q4 2020, filed 11 Feb 2021.